Comments
Commented by André Will-Laudien on March 20th, 2024 | 07:30 CET
Entry prices or Sell? BioNTech, Defence Therapeutics, Lufthansa and Nvidia in focus
The stock market keeps running and running - but in reality, it is just a handful of stocks that make waves every day. Investors should now be vigilant because, like the recent correction in Bitcoin, the major indices could also fall by 10%. Of course, nobody is thinking about this at the moment; the mood is too good, almost euphoric, considering Germany's precarious economic situation. We analyze technical trends and fundamental assessments to ensure everything in your portfolio goes smoothly. In our view, BioNTech, Defence Therapeutics, and Lufthansa are on the runway, but when it comes to Nvidia, you should start deploying the parachute slowly. What is next here?
Read
Commented by Stefan Feulner on March 20th, 2024 | 07:15 CET
Pure growth - Super Micro Computer, Royal Helium, Rheinmetall
After weeks of chasing records, equities, precious metals, and cryptocurrencies are taking a breather, at least in the short term, ahead of today's decision by the US Federal Reserve. The current key interest rate decision and, above all, the Fed's quarterly projections on economic development, interest rates, and inflation will likely continue to shape events afterwards. The pause will likely be short-lived if positive signals regarding earlier than planned interest rate cuts are announced.
Read
Commented by Armin Schulz on March 20th, 2024 | 07:00 CET
RWE, Almonty Industries, Nel ASA - Emission-free energy as a booster for the portfolio?
The search for an emission-free energy future is one of the most urgent undertakings of our time. In the face of increasing climate challenges and the growing need to reduce global carbon emissions drastically, innovative energy solutions are becoming the focus of scientific and public attention. At the heart of this energy revolution lie three key technologies: Fusion reactors, renewables and hydrogen. These three fields of technology form the cornerstones of an emission-free energy future. They promise not only a sustainable energy supply but also the transformation of our energy systems towards greater efficiency, security and climate compatibility.
Read
Commented by Stefan Feulner on March 19th, 2024 | 07:15 CET
Nvidia, Manuka Resources, Aurora Cannabis - All the rage
The stock markets continue to boom. The DAX was able to climb above the psychologically important 18,000-point mark, at least in the short term, while other asset classes, such as gold and Bitcoin, also reached new highs. By contrast, different sectors, such as hydrogen and cannabis, have continued to plummet in recent weeks. The latter, in particular, has received an upward boost from the US government's statements, which could herald a trend reversal.
Read
Commented by Armin Schulz on March 19th, 2024 | 07:00 CET
Volkswagen, Defense Metals, BYD, Rheinmetall - China's weapon in the tech race
In the shadow of global power rivalries, rare earths play a crucial role, not only for the defense industry, but also for the booming electric vehicle market and the production of catalytic converters in the automotive industry. These metals are the invisible backbone powering high-tech devices and are of strategic importance for the global economy and security. China's dominance in extracting and processing such resources - as illustrated by Deng Xiaoping's statement: "The Middle East has oil. China has rare earths." - sheds light on potential geopolitical tensions and highlights the importance of supply chain diversification and resilience.
Read
Commented by André Will-Laudien on March 19th, 2024 | 06:30 CET
Pay attention now - 100% performance possible with BioNTech, Bayer, Cardiol Therapeutics or HelloFresh
For investors in the biotech sector, 2024 is starting much like the previous year ended. Everyone is waiting for the big bang, which has yet to materialize. However, now that there is no longer a pandemic and cancer research is still stuck in a rut, selection has become crucial. Investing only in the future is no longer a guarantee of profit; instead, it is much more important to identify the most innovative business models and follow them. BioNTech does not currently have a blockbuster but has a good EUR 17 billion in its coffers. Bayer has seen its share price drop fivefold since 2019, and HelloFresh is also unable to keep its promises. By contrast, Cardiol Therapeutics has experienced a true rally. What lies next here?
Read
Commented by Fabian Lorenz on March 14th, 2024 | 06:30 CET
Aixtron, Standard Lithium, Edison Lithium: Up to 200% upside potential!
The Aixtron share is working on a comeback. The last few trading days have been positive, and an analyst commentary also gives hope that the crash is over. After all, the medium-term prospects of the plant engineering company are considered promising. Lithium also appears to be recovering. The long-term prospects for the sector are promising. In the case of Standard Lithium, support at USD 1 has held, and analysts see a price potential of more than 200%. At Edison Lithium, a spin-off is creating price fantasy. Will the IPO of the cobalt business bring about a turnaround? In its core business, the Company is focusing on the raw material for the next generation of batteries.
Read
Commented by Armin Schulz on March 13th, 2024 | 07:30 CET
HelloFresh, Royal Helium, Evotec - Rebounds in sight
Despite all the various challenges in today's world, such as geopolitical tensions or inflation, the stock market indices have managed to climb upwards. Investors are faced with a crucial question: Where is the hidden value in a market that has already broken many records? The answer could lie in those stocks that have so far stood on the sidelines of the great rally - the silent but potentially strong performers waiting for their rebound. This strategy shifts the focus away from the usual suspects who have already posted substantial gains to stocks that are ready to initiate their own rebound, potentially unlocking significant value for patient investors in the process. We have identified three such candidates.
Read
Commented by Fabian Lorenz on March 13th, 2024 | 06:30 CET
Bayer disappoints, BioNTech share gives hope, and Cardiol Therapeutics with upside potential!
Analysts were anticipating a more favourable outcome from Bayer's Capital Markets Day. While the spin-off of Aspirin and Co. was expected, and there was also more transparency in the legal disputes, the actual results differed significantly. In some cases, analysts' share price targets plummeted by nearly 50%. In contrast, analysts have renewed their "Buy" recommendation for Cardiol Therapeutics shares. The specialist in cardiovascular diseases is facing exciting weeks and the share could certainly still more than double. There is also movement at BioNTech. In addition to operating figures, there will soon be an update on the drug pipeline. The question remains whether the share can halt its downward trend.
Read
Commented by André Will-Laudien on March 12th, 2024 | 07:15 CET
Profit-taking in Defense and AI - What else is going on? Rheinmetall, Almonty Industries, Renk and Hensoldt
Armaments stocks have been on the sunny side in the current year, 2024. Investors in this segment clearly outperformed the DAX 40 index. Due to the geopolitical situation and a redefined EU security policy, investors have rediscovered the sector. NATO member states are being called upon by the US to strictly adhere to or further increase their percentage of gross domestic product invested in defense. Donald Trump, who may return, wants to deny renegade allies the backing of the US in an emergency. Although nobody believes in this scenario, the announcement has had the effect that orders for new armaments technology have reached a new all-time high. Which shares are still in focus?
Read